These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8380661)

  • 1. Attachment of neutralizing antibodies stabilizes the capsid of poliovirus against uncoating.
    Wetz K
    Virology; 1993 Feb; 192(2):465-72. PubMed ID: 8380661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenicity and immunogenicity of poliovirus capsid proteins.
    van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
    Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking of a human rhinovirus neutralizing antibody onto the viral capsid.
    Tormo J; Centeno NB; Fontana E; Bubendorfer T; Fita I; Blaas D
    Proteins; 1995 Dec; 23(4):491-501. PubMed ID: 8749845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.
    Crainic R; Blondel B; Horaud F
    Dev Biol Stand; 1983; 55():185-9. PubMed ID: 6329856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
    Thorpe R; Minor PD; Mackay A; Schild GC; Spitz M
    J Gen Virol; 1982 Dec; 63(2):487-92. PubMed ID: 6185628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature.
    Li Q; Yafal AG; Lee YM; Hogle J; Chow M
    J Virol; 1994 Jun; 68(6):3965-70. PubMed ID: 7514682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monospecific antisera against capsid polypeptides of poliovirus type 1 distinguish antigenic structures of poliovirus proteins.
    Wiegers KJ; Dernick R
    J Gen Virol; 1983 Apr; 64 (Pt 4)():777-85. PubMed ID: 6300300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
    van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
    Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A technique to detect the reaction between poliovirus structural polypeptides and neutralizing anti-polio IgG.
    Blondel B; Crainic R
    Dev Biol Stand; 1981; 47():335-7. PubMed ID: 6262158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template.
    Cello J; Paul AV; Wimmer E
    Science; 2002 Aug; 297(5583):1016-8. PubMed ID: 12114528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.
    Wetz K; Willingmann P; Zeichhardt H; Habermehl KO
    Arch Virol; 1986; 91(3-4):207-20. PubMed ID: 3022677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of specificity of antibodies contained in antiserum against poliovirus with mutants resistant to inhibitors in equine serum.
    Urasawa S; Urasawa T; Kanamitsu M
    J Immunol; 1974 Aug; 113(2):537-42. PubMed ID: 4367633
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disoxaril stabilization and immunogenicity of poliovirus procapsids.
    Rombaut B; Brioen P; Boeyé A
    J Gen Virol; 1990 May; 71 ( Pt 5)():1081-6. PubMed ID: 2161045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
    van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
    Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.
    Mayr GA; Chinsangaram J; Grubman MJ
    Virology; 1999 Oct; 263(2):496-506. PubMed ID: 10544121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.
    Burns CC; Shaw J; Campagnoli R; Jorba J; Vincent A; Quay J; Kew O
    J Virol; 2006 Apr; 80(7):3259-72. PubMed ID: 16537593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
    Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
    Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.